These include for KE1: the Direct Peptide Reactivity Assay (DPRA), the Amino acid Derivative Reactivity Assay (ADRA) and kinetic Direct Peptide Reactivity Assay (kDPRA) (OECD TG 442C) (2021b); for KE2: the ARE-Nrf2 Luciferase Test Method (KeratinoSensTM and LuSens, OECD TG 442D) (2018a); for KE3: the human Cell Line Activation Test (h-CLAT), U937 cell line activation Test (U-SENSTM) and Interleukin-8 Reporter Gene Assay (IL-8 Luc assay), Genomic Allergen Rapid Detection (GARDTM) for the detection of skin sensitization (GARDskinTM) (OECD TG 442E) (2018b). This evidence concerns the gene CXCL8 and skin sensitization.